A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib Study of Abemaciclib (VerzenioTM) in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Sponsor: Brown University
Terminated
Funding withdrawn
Other terminated trials from Brown University
Other Renal Cell Carcinoma Metastatic trials with similar outcome
This PHASE1 trial investigates Renal Cell Carcinoma Metastatic and is currently terminated or withdrawn. Brown University leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jan 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Oct 2019 — Dec 2019 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jul 2019 — Oct 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brown University
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .